Novartis challenges Indian patent laws
India is known as the 'Pharmacy of the developing world' for producing and supplying affordable generic drugs to more than 150 developing countries in Asia, Africa and Latin America.
But India's capacity to provide affordable drugs to millions of people is being threatened by the multinational health products compant Novartis, which is challenging a critical health safeguard - section 3(d) of Indian Patent Law in the Supreme Court of India.
If Novartis win this case India will be forced to grant more and more patents that will eventually result in killing generic production - for example of HIV drugs - and increasing drug prices exorbitantly.
ACT UP Basel have organised a petition against this case which they will present to Novartis in February.
All content contained within this website is copyright © AFAO, unless otherwise stated. Content may be reproduced for non-commercial, personal research or educational purposes free of charge, provided the following citation is made: "Reprinted from [name of publication], published by the Australian Federation of AIDS Organisations". Contact AFAO regarding other uses of content.
